CVRx, Inc. (CVRX)

NASDAQ: CVRX · IEX Real-Time Price · USD
13.70
-0.24 (-1.72%)
Dec 9, 2022 3:59 PM EST - Market closed
-1.72%
Market Cap 286.94M
Revenue (ttm) 18.95M
Net Income (ttm) -41.46M
Shares Out 20.58M
EPS (ttm) 66.29
PE Ratio 0.21
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,891
Open 14.1
Previous Close 13.94
Day's Range 13.11 - 14.1
52-Week Range 4.6 - 14.7
Beta n/a
Analysts Buy
Price Target 15.05 (+9.9%)
Earnings Date Nov 1, 2022

About CVRX

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated i... [Read more]

Industry Medical Devices
IPO Date Jun 30, 2021
Employees 109
Stock Exchange NASDAQ
Ticker Symbol CVRX
Full Company Profile

Financial Performance

In 2021, CVRx, Inc.'s revenue was $13.04 million, an increase of 115.36% compared to the previous year's $6.05 million. Losses were -$43.08 million, 205.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price forecast is 15.05, which is an increase of 9.85% from the latest price.

Price Target
$15.05
(9.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CVRx to Present at the Piper Sandler 34th Annual Healthcare Conference

MINNEAPOLIS, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”),  a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutio...

3 weeks ago - GlobeNewsWire

CVRx Launches new Barostim NEO2™ Implantable Pulse Generator

The new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians

1 month ago - GlobeNewsWire

CVRx to Attend Upcoming Investor Conferences

MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solution...

1 month ago - GlobeNewsWire

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 14.29% and 5.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

CVRx Reports Third Quarter 2022 Financial and Operating Results

Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year

1 month ago - GlobeNewsWire

CVRx to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call on November 1st, 2022

MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solution...

1 month ago - GlobeNewsWire

CVRx to Present at the Canaccord Genuity 42nd Annual Growth Conference

MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solution...

4 months ago - GlobeNewsWire

CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 0% and 6.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

CVRx Reports Second Quarter 2022 Financial and Operating Results

Second quarter 2022 revenue of $5.0 million, a 61% increase over prior year Second quarter 2022 revenue of $5.0 million, a 61% increase over prior year

4 months ago - GlobeNewsWire

CVRx to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call

MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solution...

4 months ago - GlobeNewsWire

CVRx Launches a new Barostim™ Programmer

The new Barostim Programmer launches in the U.S., making Barostim therapy programming simpler and enabling remote view access to enhance customer support The new Barostim Programmer launches in the U.S....

4 months ago - GlobeNewsWire

CVRx (CVRX) Soars 5.6%: Is Further Upside Left in the Stock?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

5 months ago - Zacks Investment Research

CVRx to Present at the William Blair 42nd Annual Growth Stock Conference

MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions...

6 months ago - GlobeNewsWire

CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System

Heart failure patients implanted with Barostim can now receive conditional MRI scans

7 months ago - GlobeNewsWire

CVRx Reports First Quarter 2022 Financial and Operating Results

First Quarter 2022 Revenue of $4.1 million, a 43% Increase Over Prior Year First Quarter 2022 Revenue of $4.1 million, a 43% Increase Over Prior Year

7 months ago - GlobeNewsWire

CVRx to Report First Quarter 2022 Financial and Operating Results and Host Conference Call

MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutio...

7 months ago - GlobeNewsWire

CVRx Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year

9 months ago - GlobeNewsWire

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results

MINNEAPOLIS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solution...

10 months ago - GlobeNewsWire

CVRx to Present at the 40th Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solution...

11 months ago - GlobeNewsWire

CVRx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

MINNEAPOLIS, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive n...

1 year ago - GlobeNewsWire

CVRx Added to Russell 2000® and 3000® Indexes

MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and mini...

1 year ago - GlobeNewsWire

CVRx Reports Second Quarter 2021 Financial and Operating Results

Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year

1 year ago - GlobeNewsWire

CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference

MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive n...

1 year ago - GlobeNewsWire

CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive ...

1 year ago - GlobeNewsWire

CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors

MINNEAPOLIS, July 12, 2021 (GLOBE NEWSWIRE) -- CVRx , Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive...

1 year ago - GlobeNewsWire